VVP
LGND icon

Venture Visionary Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Venture Visionary Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-641
Closed -$35.7K – 1070
2022
Q2 		$35.7K Buy
+641
New +$36.4K ﹤0.01% 881

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Venture Visionary Partners's LGND Position: Q3 2022 in Review

Venture Visionary Partners sold out of Ligand Pharmaceuticals (LGND) in Q3 2022, closing a stake of 641 shares — an estimated $35.7K sold.

Venture Visionary Partners first reported a position in LGND in Q2 2022 and held it in 1 quarter. The position peaked at $35.7K in Q2 2022. 205 funds tracked by Wall St. Rank hold LGND as of Q3 2022.

  • Venture Visionary Partners reported no remaining Ligand Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 641 Ligand Pharmaceuticals shares in Q3 2022, an estimated $35.7K.
  • Venture Visionary Partners first reported a position in Ligand Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Ligand Pharmaceuticals position peaked at $35.7K in Q2 2022.
  • 205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.